临床使用场景对美国HIV核酸检测即时检测技术开发的关键作用
该文以美国HIV核酸检测(NAT)即时检测(POC)为例,指出全球范围内临床使用场景和价值主张已明确,但美国超80%感染病诊断在参考实验室完成,周转时间长。作者旨在开发HIV NAT的临床使用场景及技术规格,以推动商业化和有意义采纳,并认为无POC HIV NAT则美国难以实现HIV消除目标。
要点
- 美国超80%感染病诊断在参考实验室完成,周转时间相对较长。
- COVID-19催化NAT创新使POC检测成本下降,为HIV POC NAT开发提供契机。
- 开发HIV NAT临床使用场景和技术规格可推动商业化与有意义采纳。
核心结论
- 若无POC HIV NAT,美国可能难以实现HIV消除的集体目标。
研究设计与样本
- 本文为案例研究,以美国HIV核酸检测即时检测为对象,开发临床使用场景与技术规格。
主要发现
- 美国超过80%的感染病诊断在参考实验室完成,这些实验室通量高但周转时间相对较长。
- COVID-19大流行催化了核酸检测创新,使POC检测成本下降。
临床怎么用
- 临床使用场景与技术规格的明确有助于推动HIV POC NAT的商业化和有意义采纳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In global settings, both the clinical use case and value proposition have been well articulated. This has led to the development of many point-of-care (POC) diagnostics for infectious diseases. However, in the United States, more than 80% of infectious disease diagnostics are performed in reference laboratories that have high throughput but relatively long turnaround times. As the cost of POC assays has decreased with nucleic acid test (NAT) innovation catalyzed by the coronavirus disease 2019 pandemic, we sought to develop clinical use cases for human immunodeficiency virus (HIV) NATs and the technical specifications that would tip the value proposition toward commercialization and meaningful adoption. Without POC HIV NATs, we are unlikely to achieve our collective goal of HIV elimination in the United States.
引用
- Manabe YC, Hamill MM, Palamountain KM, et al. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States. Clin Infect Dis. 2026. PMID: 41128485. doi:10.1093/cid/ciaf510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。